|
ACE genotype and allele distributions among controls and migraine patients in a Norwegian population |
||||||
| Genotypes |
Alleles |
|||||
|
|
||||||
| N |
DD(%) |
ID(%) |
II(%) |
D(%) |
I(%) |
|
|
|
||||||
| Controls |
403 |
92 (26.6) |
204 (50.6) |
107 (22.8) |
388 (48.1) |
418 (51.9) |
| Migraine |
347 |
78 (22.5) |
186 (53.6) |
83 (23.9) |
342 (49.3) |
352 (50.7) |
| MwA subgroup |
155 |
34 (21.9) |
87 (56.1) |
34 (21.9) |
155 (50.0) |
155 (50.0) |
| MoA subgroup |
187 |
43 (23.0) |
96 (51.3) |
48 (25.7) |
182 (48.7) |
192 (51.3) |
| Lisinopril responders |
12 |
2 (16.7) |
6 (50.0) |
4 (33.3) |
10 (41.7) |
14 (58.3) |
| Lisinopril non-responders |
37 |
10 (27.0) |
16 (43.2) |
11 (29.7) |
36 (48.6) |
38 (51.4) |
| Candesartan responders* |
18 |
7 (38.9) |
9 (50.0) |
2 (11.1) |
23 (63.9) |
13 (36.1) |
| Candesartan non-responders* |
38 |
8 (21.1) |
18 (47.4) |
12 (31.6) |
34 (44.7) |
42 (55.3) |
| Responders combined |
30 |
9 (30.0) |
15 (50.0) |
6 (20.0) |
33 (55.0) |
27 (45.0) |
| Non-responders combined |
75 |
18 (24.0) |
34 (45.3) |
23 (30.7) |
70 (46.7) |
80 (53.3) |
|
* Response data available in 56 of 59 genotyped Allele and genotype frequency distributions are not significantly different for any diagnostic groups (migraine, MwA, MoA) vs controls, or for responders vs non-responders (p > 0.05). | ||||||
Tronvik et al. BMC Neurology 2008 8:4 doi:10.1186/1471-2377-8-4 |
||||||